S3022 Data in Action: Improved Patient Adherence Using a Novel IBD Dashboard. Results of a Multi-Site 6-Month Pilot

Introduction: Effective IBD management requires close clinical and laboratory monitoring with proactive treatment adjustments. Despite published guidelines, variability in care highlights the need for data-driven approaches to assess and improve adherence. We leveraged a novel actionable data-fed IBD Dashboard to assess practice performance in real time and measured success over a 6-month pilot with 9,795 active IBD patients in 6 community-based GI practices across 4 states. Methods: Six key performance indicators (KPIs) aligned with evidence-based treat-to-target STRIDE-II recommendations were chosen by a key opinion leader group. Our primary aim was to use a novel IBD Dashboard to improve KPI adherence. KPIs measured annual patient attrition rate, annual laboratory protocol adherence, colonoscopy completion rate every 2 years for those on advanced therapy, advanced therapy use in high-risk patients, prescription patterns of mesalamine for Crohn’s disease, and enrollment in chronic care management. Six sites were chosen from 144 locations, with each site selecting a champion to implement and oversee the pilot. Staff were trained to use the Dashboard consistently, and monthly meetings addressed current performance, identification of barriers, and workflow adjustments. A 2-proportion z-test was used for statistical analysis of aggregated data for comparison of baseline to conclusion of pilot. Results: Significant improvement across multiple metrics were identified, including a reduction in patient attrition from 33% to 26% (P < 0.0001); lab testing rate increased from 23% to 26% (P < 0.0001); colonoscopy completion rate rose from 63% to 67% (P = 0.003); and advanced therapy treatment rate increased from 25% to 28% (P = 0.006). Through patient identification, 407 patients that had failed to follow up were scheduled for an office visit. At pilot conclusion, 297 completed the scheduled office visit; of these, 65 had a colonoscopy, 57 were started or switched to a biologic, and 32 on a small molecule. Conclusion: This pilot is the first IBD Dashboard initiative with in-progress expansion across a 22-state, community-based GI practice. Unlike prior efforts confined to single sites or regional centers, this project demonstrates scalable improvement in IBD care. Care processes are now proactive and standard at all 6 sites and are expanding into other disease states. Future AI integration will support broader data curation and KPI enhancement.